Newsroom | 229182 results

RAHWAY, N.J.--(BUSINESS WIRE)--The Biologics License Application (BLA) seeking accelerated approval in the U.S. for Daiichi Sankyo (TSE: 4568) and Merck’s (NYSE: MRK), known as MSD outside of the United States and Canada, ifinatamab deruxtecan (I-DXd) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy has been voluntarily withdrawn. The decision to withdraw the BLA is based on discussions wit...

TOKYO--(BUSINESS WIRE)--The Biologics License Application (BLA) seeking accelerated approval in the U.S. for Daiichi Sankyo (TSE: 4568) and Merck’s (NYSE: MRK), known as MSD outside of the United States and Canada, ifinatamab deruxtecan (I-DXd) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy has been voluntarily withdrawn. The decision to withdraw the BLA is based on discussions with the U...

TORONTO--(BUSINESS WIRE)--Elmhurst® 1925, maker of the world’s finest plant-based foods and beverages, introduces Clean Protein™ in the Canadian market. The ready-to-drink plant-based protein beverage delivers 27g of complete protein with just 190 calories and absolutely no gums, seed oils, or artificial sweeteners, underscoring Elmhurst’s commitment to simple ingredients, superior performance, and the cleanest ingredient lists in an entirely new category for the brand – RTD protein. Anchoring...

FRANKLIN, Tenn.--(BUSINESS WIRE)--Acadia Healthcare Company, Inc. (“Acadia” or the “Company”) (NASDAQ: ACHC) issues the below summary notice of proposed settlement as provided for in the September 1, 2026 order providing preliminary approval issued by the United States District Court for the Middle District of Tennessee. UNITED STATES DISTRICT COURT MIDDLE DISTRICT OF TENNESSEE NASHVILLE DIVISION IN RE ACADIA HEALTHCARE COMPANY, INC. STOCKHOLDER DERIVATIVE LITIGATION Lead Case No. 3:19-cv-00167...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced that the Company will report clinical data from the Phase 1 study evaluating prulacabtagene leucel (prula-cel) as a potential treatment for patients with systemic lupus erythematosus with or without lupus nephritis...

LEOBENDORF, Autriche--(BUSINESS WIRE)--Croma-Pharma lance saypha® volume prime Lidocaine, un produit de comblement dermique à base d'acide hyaluronique réticulé qui remplace saypha® volume Lidocaine au sein de la gamme saypha® de l'entreprise. Ce nouveau produit offre aux médecins une solution davantage polyvalente, comprenant des indications élargies à la fois pour la volumisation de la zone médio-faciale et pour le traitement des sillons nasogéniens, toutes deux étayées par de solides données...

LEOBENDORF, Austria--(BUSINESS WIRE)--Croma-Pharma presenta saypha® volume prime con lidocaina, un filler dermico a base di acido ialuronico reticolato che sostituisce saypha® volume con lidocaina all'interno del portafoglio di prodotti saypha® dell'azienda. Il nuovo prodotto offre ai medici una soluzione più versatile con indicazioni più ampie sia per la volumizzazione del terzo medio del viso che per le pieghe nasolabiali, supportate da solidi dati clinici.1,2 saypha® volume prime con lidocai...

LEOBENDORF, Austria--(BUSINESS WIRE)--Croma-Pharma presenta saypha® volume prime Lidocaine, un relleno dérmico de ácido hialurónico reticulado que sustituye a saypha® volume Lidocaine dentro de la gama saypha® de la empresa. El nuevo producto ofrece a los médicos una solución más versátil con más aplicaciones, tanto para la reposición de volumen en la zona media del rostro como para los pliegues nasolabiales, con el respaldo de importantes datos clínicos.1,2 saypha® volume prime Lidocaine demos...

WILMINGTON, Del.--(BUSINESS WIRE)--InSilicoTrials, a cloud-based platform for AI and computational modeling and simulation in healthcare, today announced that it is a subawardee on a team led by Sage BioNetworks, which has received an award from the Advanced Research Projects Agency for Health (ARPA-H) under the Critical Illness Immunological Reprogramming and Control Point Learning Engine (CIRCLE) program. Critical illness, including severe infections, traumatic injuries and complications of c...

MIAMI-DADE, Fla. & BROWARD, Fla. & PALM BEACH, Fla. & DUVAL, Fla. & HILLSBOROUGH, Fla.--(BUSINESS WIRE)--Little more than half (52%) of respondents, and less than half (43%) of those aged 30-39, are very aware that breast cancer diagnoses have been rising among younger patients, according to a poll of more than 1,000 Florida-based women. Findings show 32% are somewhat aware of this increase, and 17% are either not very aware (11%) or not at all aware (6%). Conducted by the TopLine MD Alliance —...